Search by Drug Name or NDC
NDC 44087-0044-03 REBIF 44 ug/.5mL Details
REBIF 44 ug/.5mL
REBIF is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by EMD Serono, Inc.. The primary component is INTERFERON BETA-1A.
MedlinePlus Drug Summary
Interferon beta-1a intramuscular injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
Related Packages: 44087-0044-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Interferon Beta-1a Intramuscular Injection
Interferon beta-1a subcutaneous injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
Related Packages: 44087-0044-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Interferon Beta-1a Subcutaneous Injection
Product Information
NDC | 44087-0044 |
---|---|
Product ID | 44087-0044_348c7db6-5713-4329-83ca-14925b9b1d69 |
Associated GPIs | 6240306045E540 |
GCN Sequence Number | 050039 |
GCN Sequence Number Description | interferon beta-1a/albumin SYRINGE 44MCG/.5ML SUBCUT |
HIC3 | H0E |
HIC3 Description | AGENTS TO TREAT MULTIPLE SCLEROSIS |
GCN | 15918 |
HICL Sequence Number | 023353 |
HICL Sequence Number Description | INTERFERON BETA-1A/ALBUMIN HUMAN |
Brand/Generic | Brand |
Proprietary Name | REBIF |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | interferon beta-1a |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 44 |
Active Ingredient Units | ug/.5mL |
Substance Name | INTERFERON BETA-1A |
Labeler Name | EMD Serono, Inc. |
Pharmaceutical Class | Interferon beta [EPC], Interferon-beta [CS] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA103780 |
Listing Certified Through | 2024-12-31 |
Package
NDC 44087-0044-03 (44087004403)
NDC Package Code | 44087-0044-3 |
---|---|
Billing NDC | 44087004403 |
Package | 12 SYRINGE, GLASS in 1 CARTON (44087-0044-3) / .5 mL in 1 SYRINGE, GLASS (44087-0044-9) |
Marketing Start Date | 2002-03-07 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 1441.54 |
Pricing Unit | ML |
Effective Date | 2021-01-15 |
NDC Description | REBIF 44 MCG/0.5 ML SYRINGE |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 4, 5 |
Classification for Rate Setting | B |
As of Date | 2022-01-12 |